Ashling Wahner

Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.

Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.

Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.

Trastuzumab deruxtecan did not meet the prespecified efficacy criterion in HER2-low salivary gland carcinoma, though responses were observed in salivary duct carcinoma.

Catch up on insights into the global development of breast cancer treatments in the global spotlight.

Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.

The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.

Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.

In a phase 3 trial analysis, DCVax-L extended OS compared with individual patient data from external control populations in patients with glioblastoma.

The FDA gave a CRL to the NDA seeking the approval of Orviglance for use in the detection of liver metastases in patients with severe kidney impairment.

Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.

Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.

The FDA has issued a CRL to LNTH-2501 for the localization of SSTR-positive NETs.

Milana V. Dolezal, MD, MSci, notes how the CLEOPATRA trial paved the way for further breast cancer research and highlighted data from DESTINY-Breast09.

Real-world treatment with pegylated interferon alfa-2a tolerable, and treatment-related AEs were manageable in patients with cutaneous T-cell lymphoma.

Dibotatug was deemed tolerable and produced robust responses across subgroups of patients with relapsed/refractory cytotoxic T/NK cell lymphomas.

BI-1808 as a single agent and in combination with pembrolizumab elicited responses and was generally well tolerated in patients with CTCL.

In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.

Topical tofacitinib is tolerable and has shown preliminary efficacy in patients with early-stage mycosis fungoides.

Izalontamab brengitecan has been approved in China for recurrent/metastatic NPC following disease progression on chemotherapy and PD-1/PD-L1 inhibition.

Priya Rastogi, MD, discusses findings from a sub-study of the GeparDouze trial evaluating the effects of ctDNA positivity on treatment outcomes in TNBC.

The European Commission approved first-line sacituzumab govitecan as monotherapy for unresectable/metastatic TNBC not eligible for PD-(L)1 inhibition.

Patients with metastatic breast cancer achieving a CR/deep PR with frontline T-DXd/pertuzumab had the most durable PFS outcomes in DESTINY-Breast09.

Starting TTFields with chemoradiotherapy did not significantly improve OS vs using TTFields in the maintenance phase in newly diagnosed glioblastoma.

Phase 1 data show that BGB-16673 is eliminated through intestinal and biliary excretion, limiting CYP3A-mediated interactions.

A retrospective analysis of 3234 patients with CLL/SLL showed that over half of those 75 to 79 years of age went on to receive second-line therapy.

Experts unpack key melanoma data shared during the 2026 ASCO Annual Meeting.